Table 4.
The success rate of cefaclor for all patients and that for patients with secondary treatment
| All (n = 233) | < 50 years (n = 34) | > 50 years (n = 199) | |||||
|---|---|---|---|---|---|---|---|
| Success | Fail | Success | Fail | Success | Fail | P value | |
| All | 219 (94.0) | 14 (6.0) | 33 (97.1) | 1 (2.9) | 186 (93.5) | 13 (6.5) | < 0.001 |
| Pathogens with the failure of cefaclor | |||||||
| Escherichia coli | 156 (97.5) | 4 (2.5) | 33 (97.1) | 1 (2.9) | 128 (97.7) | 3 (2.3) | 0.975 |
| Klebsiella species | 18 (94.7) | 1 (5.3) | 1 (100) | 0 | 17 (94.4) | 1 (5.6) | 0.971 |
| Escherichia coli-ESBL | 11 (61.1) | 7 (38.9) | 1 (100) | 0 | 10 (58.8) | 7 (41.2) | 0.714 |
| Staphylococcus species | 5 (83.3) | 1 (16.7) | 2 (100) | 0 | 3 (75.0) | 1 (25.0) | 0.741 |
| Enterococcus faecalis | 3 (75.0) | 1 (25.0) | 0 | 0 | 3 (75.0) | 1 (25.0) | 1 |
Unless otherwise stated, the number of patients with percentages in parentheses
ESBL Extended spectrum beta-lactamase